Navigation Links
Aventis Pays More Than $190 Million to Settle Drug Pricing Fraud Matters
Date:9/10/2007

WASHINGTON, Sept. 10 /PRNewswire-USNewswire/ -- Aventis Pharmaceuticals Inc. has paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company's alleged fraudulent pricing and marketing of drugs, the Justice Department announced today. Aventis is now known as sanofi-aventis U.S. Inc. and sanofi-aventis U.S. LLC.

Aventis, one of the world's largest pharmaceutical manufacturers, has agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. The government alleged that the pharmaceutical company engaged in a scheme to set and maintain fraudulent and inflated prices for Anzemet knowing that federal health care programs established reimbursement rates based on those prices.

The United States alleged that Aventis used the difference between the inflated prices that it reported, which were used by federal programs to set reimbursement rates for health care providers, and the actual prices for the drugs charged to its customers in order to market, promote and sell Anzemet to existing and potential customers.

The difference between the reimbursement rate of the federal health care programs and the actual price paid by health care providers is commonly known as the "spread." The larger the spread on a drug, the larger the profit or return on investment for the provider. Because reimbursement from federal programs was based on the fraudulent, inflated prices, the United States contended that Aventis caused false and fraudulent claims to be submitted to federal health care programs.

"Marketing drugs to doctors based on potential profits undermines confidence in the integrity of our health care system bec
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Sanofi-Aventis Allows Thais To Make Plavix
4. Drug May Make Breathing Easier for Millions
5. Hundred million dollar gift for malaria institute
6. George Bush pledges 200 million dollars for AIDS relief
7. Over Six Million HIV Infected People In South Africa- Finds A Survey
8. Hope for 11 million children facing death from illnesses
9. The forgotten epidemic killing millions
10. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
11. Tanzanian Government Sanctions $20 Million For AIDS Arug
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 2Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 3Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 4Health News:Aethlon Medical Discloses New HIV/AIDS Treatment Data 5Health News:Dr. Gunther von Hagens 'HUMAN SAGA' Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life. 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 3Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 4Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 5Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 6Health News:Probiotics may be able to help you keep fit and slim 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 3Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 4Health News:Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation 2Health News:Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation 3
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Stevens team wins First Place in ISPE Student Poster Competition 10962 1New AERIUS Cell Phones Direct Microwave Signals Away from Users 62464 1New AERIUS Cell Phones Direct Microwave Signals Away from Users 62464 2Dr Alan F Dowling Named AHIMAs Next Chief Executive Officer 62460 1Dr Alan F Dowling Named AHIMAs Next Chief Executive Officer 62460 2